Table 5. % ID g−1 of tumour and tumour/normal tissue ratios for MAb FSP 77 conjugates.
|
Ratio
|
|||||
|---|---|---|---|---|---|
| Conjugate+DOL | % ID g−1 tumour | Tumour/blood | Tumour/muscle | Tumour/colon | Tumour/small int. |
| PS 1 (2.8) | 6.4±4.7 | 0.6±0.1 | 6.1±0.4 | 9.1±0.4 | 7.2±0.6 |
| PS 1 (2.3) | 7.4±2.2 | 0.6±0.2 | 5.6±0.2 | 10.6±2.7 | 5.3±2.2 |
| PS 1 (1.6) | 6.8±0.2 | 0.9±0.7 | 3.35±2.8 | 7.5±0.3 | 3.75±2.2 |
| PS 2 (1.6) | 8.5±2.1 | 1.06±0.1 | 9.2±6.3 | 13.8±8.7 | 10.7±6.4 |
| PS 2 (2.0) | 5.3±0.2 | 0.6±0.2 | 5.2±0.5 | 8.6±4.1 | 5.6±0.9 |
| PS 2 (2.0) | 4.2±0.1 | 0.6±0.1 | 4.4±0.4 | 7.0±0.5 | 5.5±0.1 |
% ID g−1=percent of injected dose per gram of tissue; MAb=monoclonal antibodies; DOL=degree of labeling; PS=photosensitisers. Values were obtained 24 h postinjection (values are the means of tumour/normal ratios and % ID g−1 tumour±s.d. calculated from the three mice bearing the SKOv3 xenograft in each conjugate group).